Harvoni- Overview Harvoni, a combination of ledipasvir and sofosbuvir, is a highly effective medication used for treating chronic Hepatitis C virus (HCV). Approved by the FDA in 2014, Harvoni revolutionized the treatment landscape for HCV, offering a cure rate of over 90% for patients with the most common genotype 1 infection. The once-daily pill is well-tolerated and typically requires a 12-week course of treatment. With Harvoni therapy, patients experience minimal side effects compared to older …
Category: Hepatitis C Virus (HCV)
General overview of Sovaldi: Sovaldi, also known by its generic name sofosbuvir, is a breakthrough prescription medication used in the treatment of chronic hepatitis C virus (HCV). It was first approved by the U.S. Food and Drug Administration (FDA) in December 2013 and has since revolutionized the way HCV is treated. Sovaldi is a direct-acting antiviral agent (DAA) that works by targeting the virus’s replication process, thus reducing the viral load in the body. This …
General description of Daklinza Daklinza is a prescription drug used to treat chronic Hepatitis C Virus (HCV) infection in adults. It belongs to a class of medications known as direct-acting antivirals (DAAs), which work by targeting specific enzymes in the virus to prevent its replication and spread in the body. How Daklinza works Daklinza contains the active ingredient daclatasvir, which inhibits the action of the HCV NS5A protein, a key component in the virus’s life …